Genscript Biotech (01548): CARVYKTI generated net trade sales of approximately US$710 million for the quarter ended September 30, 2026

Zhito Finance APP news, Genscript Biotech (01548) announced that, pursuant to the collaboration and license agreement entered into between Legend Biotech Corporation (a joint venture of the Company, whose shares are listed on the Nasdaq Global Select Market in the United States in the form of American Depositary Shares) and Janssen Biotech, Inc. (Janssen) on December 21, 2017, CARVYKTI generated net trade sales of approximately US$710 million for the quarter ended September 30, 2026.